DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Jennison Associates LLC

Jennison Associates LLC grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 10.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,643,757 shares of the medical device company’s stock after purchasing an additional 710,858 shares during the period. Jennison Associates LLC’s holdings in DexCom were worth $594,455,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in DexCom by 2.2% during the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after buying an additional 214,136 shares in the last quarter. Groupama Asset Managment lifted its position in shares of DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock valued at $1,912,000 after acquiring an additional 31,358 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after acquiring an additional 876,739 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of DexCom by 11.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock worth $183,298,000 after acquiring an additional 288,381 shares in the last quarter. Finally, Champlain Investment Partners LLC grew its holdings in shares of DexCom by 8.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,213,283 shares of the medical device company’s stock worth $148,378,000 after acquiring an additional 163,210 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the subject of several analyst reports. JPMorgan Chase & Co. upped their target price on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Raymond James dropped their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Leerink Partners reduced their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $85.00 to $115.00 in a research note on Monday. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $98.41.

DexCom Stock Performance

Shares of DXCM stock opened at $86.83 on Monday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The stock’s 50-day moving average is $80.77 and its two-hundred day moving average is $76.21. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm has a market cap of $33.92 billion, a P/E ratio of 51.99, a PEG ratio of 2.23 and a beta of 1.14.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 4,259 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.